Hematopoietic Clinical Trials

248 recruitingLast updated: July 25, 2026

There are 248 actively recruiting hematopoietic clinical trials across 24 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 3, Early Phase 1, Phase 4. Top locations include Houston, Texas, United States, Rochester, Minnesota, United States, Boston, Massachusetts, United States. Updated daily from ClinicalTrials.gov.


Hematopoietic Trials at a Glance

248 actively recruiting trials for hematopoietic are listed on ClinicalTrialsFinder across 6 cities in 24 countries. The largest study group is Not Applicable with 79 trials, with the heaviest enrollment activity in Houston, Rochester, and Boston. Lead sponsors running hematopoietic studies include Mayo Clinic, M.D. Anderson Cancer Center, and City of Hope Medical Center.

Browse hematopoietic trials by phase

Treatments under study

About Hematopoietic Clinical Trials

Looking for clinical trials for Hematopoietic? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Hematopoietic trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Hematopoietic clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 248 trials

Recruiting
Not Applicable

HematoCare: Feasibility of a Survivorship Care Plan for Hematologic Cancer Patients Undergoing HSCT

SurvivorshipHematopoietic Stem Cell TransplantationCancer Survivorship+1 more
Azienda USL Reggio Emilia - IRCCS40 enrolled1 locationNCT07579065
Recruiting
Phase 1

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

Leukemia, Lymphocytic, AcuteBlood CancerMyeloid Leukemia, Acute+8 more
National Cancer Institute (NCI)86 enrolled1 locationNCT06904066
Recruiting
Not Applicable

Dental Cleaning to Prevent Chronic Graft-Versus-Host Disease

Acute Graft Versus Host DiseaseHematopoietic and Lymphatic System NeoplasmChronic Graft Versus Host Disease
Fred Hutchinson Cancer Center45 enrolled1 locationNCT07535008
Recruiting

Kinetic Analysis of Immune Cells in Blood and Chronic Graft-Versus-Host Disease-Affected Tissues After Allogeneic Hematopoietic Cell Transplantation

Hematopoietic and Lymphatic System NeoplasmMalignant Solid NeoplasmGraft-Versus-Host Disease
City of Hope Medical Center75 enrolled1 locationNCT07235501
Recruiting
Phase 1Phase 2

Study to Evaluate the Safety and Effectiveness of Withaferin A as a Treatment to Prevent GvHD in Transplant Patients

Hematopoietic Stem Cell Transplant (HSCT)Hematological MalignancyGVHD - Graft-Versus-Host Disease
Tata Memorial Centre54 enrolled2 locationsNCT07724873
Recruiting
Phase 2

Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases

Hematopoietic and Lymphatic System NeoplasmAcute Lymphoblastic LeukemiaAcute Myeloid Leukemia+7 more
Fred Hutchinson Cancer Center54 enrolled1 locationNCT06013423
Recruiting
Phase 2

Chlorophyllin for Reducing Oral Mucositis in Total Body Irradiation Prior to Transplant

Oral MucositisHematopoietic Stem Cell Transplantation (HSCT)Hematological Malignancies+1 more
Tata Memorial Centre17 enrolled1 locationNCT07709195
Recruiting
Not Applicable

The MedMemos Study: Promoting Adherence to Medications in Pediatric Bone Marrow Transplant Patients

Hematopoietic Cell Transplant
Nationwide Children's Hospital25 enrolled1 locationNCT07718204
Recruiting
Phase 2

To Study Lower Dose of Cyclophosphamide After Stem Cell Transplant for Blood Cancers

Hematological MalignanciesHaploidentical Hematopoietic Stem Cell Transplant
Tata Memorial Centre20 enrolled2 locationsNCT07719946
Recruiting
Not Applicable

Exercise and Health Counseling in Pediatric Hematopoietic Stem Cell Transplantation

Hematopoietic System--Cancer
Alejandro Lucia48 enrolled1 locationNCT06300515
Recruiting

Long-Term Follow up of Patients Undergoing Hematopoietic Stem Cell Transplantation, Cellular Therapy, or Gene Therapy

Hematopoietic Stem Cell TransplantationTissue DonorsCellular Immunotherapy, Adoptive+1 more
National Cancer Institute (NCI)2,000 enrolled1 locationNCT03000244
Recruiting
Phase 1

CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma

Hematologic MalignancyRelapsed Pediatric ALLHematopoietic Cell Transplantation
St. Jude Children's Research Hospital70 enrolled1 locationNCT07257419
Recruiting
Not Applicable

Longitudinal Early Advance Care Planning Discussions and Documentation (LEADD) Program: An Exploratory Study in Adolescents and Young Adults (AYAs) Receiving Hematopoietic Stem Cell Transplant

Hematopoietic Stem Cell Transplantation
National Cancer Institute (NCI)222 enrolled2 locationsNCT05605574
Recruiting
Phase 2

Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients

Hematopoietic and Lymphoid Cell NeoplasmInfluenza
M.D. Anderson Cancer Center60 enrolled1 locationNCT04712539
Recruiting

Quality of End-of-Life Care for Children With Cancer

Childhood Malignant Solid NeoplasmChildhood Hematopoietic and Lymphatic System Neoplasm
Children's Oncology Group2,425 enrolled15 locationsNCT07412002
Recruiting
Phase 1Phase 2

Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness

Hematopoietic and Lymphatic System NeoplasmMetastatic Malignant Solid NeoplasmStage IV Colorectal Cancer AJCC v8+4 more
National Cancer Institute (NCI)42 enrolled23 locationsNCT05691491
Recruiting
Phase 3

Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer

Hematopoietic and Lymphatic System NeoplasmMalignant Solid Neoplasm
Children's Oncology Group60 enrolled205 locationsNCT06513962
Recruiting
Not Applicable

Coping Skills Training for Symptom Management and Daily Steps (Step Up)

Hematopoietic Stem Cell TransplantCAR-T Cell Therapy
Duke University177 enrolled1 locationNCT06575712
Recruiting
Phase 1Phase 2

Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant

Hematopoietic and Lymphoid System Neoplasm
M.D. Anderson Cancer Center25 enrolled1 locationNCT04022239
Recruiting
Not Applicable

Solution-Focused Brief Therapy for Support of Psychological Distress in Adolescent and Young Adult Cancer Survivors

Hematopoietic and Lymphatic System NeoplasmMalignant Solid Neoplasm
University of Michigan Rogel Cancer Center60 enrolled1 locationNCT06941324